<p>There are 200+ fully characterized patient cases with AML (all tumor/normal pairs, 100 with relapse sample as well) that make up the TARGET AML dataset, each with gene expression, tumor  and paired normal copy number analyses, methylation and comprehensive next-generation sequencing to include whole genome sequencing, mRNA-seq and</p>

TARGET: Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute study with RNA-Seq, Targeted-Capture + 3 more data on CRDC, KFDRC (2,505 participants)